Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study
Juan W. Valle(University of Manchester), Arndt Vogel(Medizinische Hochschule Hannover), Crystal S. Denlinger(Fox Chase Cancer Center), Aiwu Ruth He(Georgetown University), Li‐Yuan Bai(China Medical University Hospital), Р. В. Орлова(St Petersburg University), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Jorge Adeva(Research Institute Hospital 12 de Octubre), Li‐Tzong Chen(National Health Research Institutes), Radka Obermannová(Masaryk Memorial Cancer Institute), Thomas J. Ettrich(University Hospital Ulm), Jen‐Shi Chen(Chang Gung University), Harpreet Wasan(Imperial College Healthcare NHS Trust), Allicia C. Girvan(Eli Lilly (United States)), Wei Zhang(Eli Lilly (United States)), Jiangang Liu(Eli Lilly (United States)), Chunlao Tang(Eli Lilly (United States)), Philip J. Ebert(Eli Lilly (United States)), Amit Aggarwal(Eli Lilly (United States)), Samuel McNeely(Eli Lilly (United States)), Brian A. Moser(Eli Lilly (United States)), Joana Oliveira(Eli Lilly (United States)), Roberto Carlesi(Eli Lilly (Italy)), Richard A. Walgren(Eli Lilly (United States)), Do‐Youn Oh(Seoul National University Hospital)
Cited by 66
Abstract
Related Papers
No related papers found
Powered by citation graph analysis